Massachusetts Society of Clinical Oncologists - FDA approves liquid biopsy NGS companion diagnostic test for multiple cancers and biomarkers

"The voice for cancer physicians and their patients in Massachusetts."

Home
Resources
FDA Approvals
FDA approves liquid biopsy NGS companion diagnostic test for multiple cancers and biomarkers

FDA approves liquid biopsy NGS companion diagnostic test for multiple cancers and biomarkers

10 Nov 2020 8:54 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved the liquid biopsy next-generation sequencing-based FoundationOne Liquid CDx test (Foundation Medicine, Inc.) as a companion diagnostic device for multiple additional biomarkers detected in cell free-DNA isolated from plasma specimens. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: msco@mms.org